Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 15/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 14/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437954 | 0.88 | GABRA2 (0.47) | GABRA2GABRB2PTGS2FAAH | |
| SCHEMBL1437572 | 0.85 | GABRA2 (0.52) | GABRA2GABRB2PTGS2FAAH | |
| SCHEMBL9893874 | 0.83 | GABRA2 (0.52) | GABRA2GABRB2PTGS2FAAH | |
| SCHEMBL1437666 | 0.83 | GABRA2 (0.39) | GABRA2GABRB2PTGS2 | |
| SCHEMBL9893997 | 0.81 | GABRA2 (0.48) | GABRA2GABRB2PTGS2 | |
| SCHEMBL1437375 | 0.74 | MDM2 (0.45) | GABRA2GABRB2 | |
| SCHEMBL1438491 | 0.73 | ADORA3 (0.38) | GABRA2GABRB2 | |
| SCHEMBL29466216 | 0.70 | GABRA2 (0.44) | GABRA2GABRB2 | |
| SCHEMBL20077798 | 0.70 | GABRA2 (0.44) | GABRA2GABRB2 | |
| SCHEMBL1440277 | 0.69 | GABRA2 (0.47) | GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | GABRA2 4293/4885GABRB2 4278/4885PTGS2 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.